STRENSIQ 100 mg/ml, solution for injection 12 bottles of 0.8 ml
Active ingredients: Asfotase alfa
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection12 bottles of 0.8 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- STRENSIQ 100 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 12 flacon(s) en verre de 0,8 ml
- Marketing authorisation holder
- ALEXION EUROPE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Jan 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69258437CIP73003116CIP133400930031162Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ASFOTASE ALFAsolution | 100 mg · 1 ml de solution injectable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.